Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways

@article{Schniewind2006CombinationPT,
  title={Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways},
  author={Bodo Schniewind and Kirsten Heintz and Roland Kurdow and Ole Ammerpohl and Anna Trauzold and Doris Emme and Peter Dohrmann and Holger Kalthoff},
  journal={Journal of Carcinogenesis},
  year={2006},
  volume={5},
  pages={25 - 25}
}
BACKGROUND Standard chemotherapy protocols in NSCLC are of limited clinical benefit. Histone deacetylase (HDAC) inhibitors represent a new strategy in human cancer therapy. In this study the combination of the HDAC inhibitor phenylbutyrate (PB) and the nucleoside analogue gemcitabine (GEM) was evaluated and the mechanisms underlying increased cell death were analyzed. METHODS Dose escalation studies evaluating the cytotoxicity of PB (0.01-100 mM), GEM (0.01-100 microg/ml) and a combination of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Histone deacetylase inhibitors differentially mediate

  • K Fronsdal, F Saatcioglu
  • apoptosis in prostate cancer cells Prostate
  • 2005

Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells

  • K Fronsdal, F Saatcioglu
  • Prostate
  • 2005
2 Excerpts

Similar Papers

Loading similar papers…